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N-Acyltyramines as Substrates for Tyrosinase: 
Enzymatic Lag and Dopamine Precursor 
 
Jacob A. Shafer 
 
ABSTRACT 
 
Tyrosinase is a widespread, highly studied and important enzyme involved in processes 
ranging from the browning of mushrooms to roles in mammalian cancer.  The enzyme 
suffers from a noticeable lag phase while the enzyme generates all necessary cofactors 
from available substrates.  There have not been significant studies of the effect on lag 
from moving through a family of substituted substrates.  This thesis reports the results of 
one such study using a family of N-acyltyramines. 
 
The selection of N-acyltyramines was ideal because the substrates in this reaction may be 
related to synthesis of N-acyldopamines, which serve many important physiological 
functions.  It was concluded that the product formed from N-acetyltyramine is 1-acetyl-
2,3-dihydro-1H-indole-6,7-dione, a quinone.
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Chapter 1 
 
Introduction 
 
Tyrosinase 
 
Tyrosinase (E.C. 1.14.18.1) is an enzyme which is distributed widely throughout all life 
forms [1].  The primary biological role is to produce melanin, which causes a darkening 
of tissues [2].  Due to its presence in mushrooms and plants, tyrosinase has been studied 
from the mid 1800s, as the related browning of harvested mushrooms was, and remains to 
be, a chief agricultural concern [3, 4].  In mammals, it was thought to be involved in 
cancer [5].  More recently, there has been interest from the cosmetic industry for finding 
inhibitors to act as skin whiteners [6] and it is being explored for its role in many types of 
albinism [7].  Tyrosinase has been considered as a tumor suppressor; however, it might 
have a role in mutagenicity as a free radical producer [8, 9].  One of the primary products 
of tyrosinase is melanin.  This is a family of pigments found in life ranging from higher 
mammals down to insets and arthropods.  Its role in higher organisms relates to 
coloration, such as hair and skin, as well as protection for solar UV radiation [10, 11].  In 
lower organisms, the role served by tyrosinase is more expansive, ranging from 
exoskeleton coloration to immune system response and wound healing [12, 13]. 
 
Scheme 1: General reaction catalyzed by tyrosinase.  R≠H. 
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The enzyme is a heterotetramer, with two heavy and two light chains for a combined 
molecular mass of 120 kDa (Figure 1) [14].  The central domain, containing the active 
site, is well conserved across the various organisms [15].  The active site is composed of 
six histidines binding two copper ions, and has binding pockets for both the substrate and 
a reductant (Figure 2). 
 
Figure 1. Structure of tyrosinase.  Coloring scheme: Cu (brown), O2 (red), NO32- (blue, red) with no 
bound substrate [16]. 
 
The enzyme’s primary mechanism occurs in two steps using molecular oxygen both to 
hydroxylate monophenols to o-diphenols and to oxidize diphenols to o-quinones (Scheme 
1) [10, 11].  Tyrosinase expresses stereospecificity with regard to binding affinity, 
favoring D-isomers, but does not show any specificity towards the reaction rate [17].  
There is ongoing research as to the exact mechanism used by tyrosinase.  Scheme 2 
shows one proposal where substrates are M, a monophenol, and D, an o-diphenol, and the 
active site states are Eox-oxytyrosinase, Em-mettyrosinase and Ed-deoxytryosinase.  In Eox, 
there is O2 bound to the Cu ions and both are in +2 oxidation state, while in Ed there is no 
oxygen moiety bound and the Cu ions are both in the +1 oxidation state, and the Em has a 
hydroxyl bound and both Cu ions are in +2 oxidation state.  In this proposal, Eox can react 
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with either D or M.  In the case of M, D is formed which can be released leaving the 
active site as Em or the final product, a quinone, can be evolved leaving tyrosinase as Ed.  
If Eox reacts with D, then the quinone is made and tyrosinase ends in Em.  Em binding with 
M is a dead-end because the hydroxyl is unable to form a new C-O bond.  In order to 
have meaningful forward movement of this reaction scheme, the enzyme needs to be 
available in the Eox state or the substrate must be a diphenol.  In most cases, however, the 
substrate is a monophenol and tyrosinase is predominately found in the Em state [18-26]. 
 
 
Figure 2. Active site of tyrosinase.  Color scheme: Cu (orange), O2 (red) and hisitidines with no 
bound substrate (generated from [16]). 
 
These two factors set-up what is known as the lag (τ) phase of the reaction.  During this 
time, a small amount of naturally occurring Eox enzyme (2-30%) is converting M to D 
where the reaction can move forward readily.  This unusual phenomenon has been 
studied to some extent and it is known that increasing the enzyme concentration will 
reduce τ, due to the increased amount of enzyme present in Eox.  Additionally, by 
increasing the substrate (M) concentration, τ will increase.  This is because k-2 is larger 
than k3 (Scheme 2) and Em is generated along with D, leaving enzyme inactive until 
enough D is accumulated to make k3 favorable, and M out competes D at the active site 
of remaining Eox [18, 20, 22, 23]. 
4 
 
Scheme 2. Proposed tyrosinase mechanism.  Em mettyrosinase, Eox oxytyrosinase, Ed deoxytryosinase, 
M monophenol, D o-diphenol, and the final product of a quinone (adapted from [21]). 
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N-Acyldopamine 
 
Dopamines have many important biological roles.  Dopamine is most widely known for 
its role as a neurotransmitter.  Also it has a primary role as a precursor in the formation of 
melanin, which is involved in pigmentation in many species and sclerotization, the 
hardening and coloring of exoskeletons, in insects [24, 26-28].  More recently the role of 
N-acyldopamine in brain and central nervous system has been explored.  N-
Arachidonoyl-, N-palmitoyl-, N-oleoyl- and N-stearoyldopamine are all known to present 
in mammals.  In the case of N-arachidonoyl- and N-oleoyldopamine, they bind to TRPV1 
and CB1 receptors which experimentally cause hyperalgesia.  Also, N-oleoyldopamine 
has been shown to reduce risk of ischemia and reperfusion injury by action on the 
TRPV1 receptor in the heart [29].  N-Palmitoyl- and N-stearoyldopmaine have an 
unknown biological role [30-33].  There is also interest in N-acyldopamines as drugs for 
both their physical and inhibitory properties.  N-Acyldopamines has been shown to self-
aggregate into micelle supramolecules and then hydrolyze slowly, gradually releasing 
dopamine to receptors [35].  In rats, there is evidence that N-acetyldopamine inhibits 
malondialdehyde production, which is tied to oxidative stress, better than the natural 
agent, melatonin [27, 36].  N-Acetyledopamine has been shown to decrease superoxide 
production in THP-1 derived human monocytes [38].  It has been discovered that N-
linoleoyldopamine is produced in plants and acts as a strong inhibitor to arachidonate 5-
lipoxygenase, a good drug target in humans for asthma [37]. 
 
N-Acyldopamine biosynthesis is not completely understood, and two competing 
pathways have been proposed (Scheme 3).  There is evidence that tyrosine can be directly 
acylated via the enzyme N-  acyltyrosine synthase followed by oxidation by tyrosinase to 
N-acyldopamine (pathway A).  An analogous pathway involves acylation of tyramine by 
an unknown enzyme.  Alternatively, acyl groups may be transferred to tyramine or 
tyrosine via acyl-coenzyme A; the resulting species would then be oxidized by tyrosinase 
(pathway B) [32, 39, 40]. 
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Tyrosine (Figure 3) has been explored to some extent in the literature, mostly as the 
primary substrate for tyrosinase with a reported KM of 1.25 mM [41].  It has been shown 
that tyrosinase can catalyze the oxidation of N-acetyltyrosine to the corresponding 
quinone [42].  Additionally, the similar family of compounds of N-acetyl-4-S-
cysteaminylphenol (Figure 3) and N-propanoyl-4-S-cysteaminylphenol have been shown 
to be substrates for tyrosinase [43].  There has also been some work suggesting that N-
methyl-, N-methoxy- and N-formyltyrosine as well as the methyl ester (Figure 3) are 
substrates for tyrosinase [19, 44-46].  On the other hand, N-acyltyramines (Figure 3) are 
not widely studied.  They have been found in trace amounts throughout the central 
nervous system of insects and mammals [47, 48].  In honeybees, there is evidence that the 
ratio of tyramine and N-acetyltyramine is dependent on the presence of a queen – causing 
workers to convert to queens as needed.  N-acetyltyramine may be a viable drug in the 
conversion of resistant state to sensitive state leukemia [49]. 
 
 
Scheme 3: Proposed biosynthetic pathways for N-acyldopamine.  A represents an acyl group.  
Pathway A is on the left, Pathway B is on the right. 
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Figure 3: Structures of tyramine, tyrosine and similar compounds. 
 
Even though most of the literature indicates that the precursors for N-acyldopamines are 
N-actyltyrosines, the recent discovery by a Russian group [39] that N-acyltyramines are 
preferred to N-acytyrosines in vivo drew our attention.  As mentioned above, N-
acyltyramines are found in tissues where N-acyldopamines are located, but it is not 
known what, if any, role they serve there.  In order to further investigate the possibility of 
N-acyltyramines acting as precursors to N-acyldopamines, a series of N-acyltyramines, 
with varying acyl chain lengths, were synthesized and evaluated as tyrosinase substrates.  
This also gave us the opportunity to study the effect acyl chain length has on τ, the 
enzymatic lag tyrosinase exhibits.  Ideally, the data will show that N-acyltyramines have 
superior kinetic parameters to tyramine.  Additionally, characterization should indicate 
the product to be N-acyldopamine or its derivatives. 
  
8 
 
 
 
 
Chapter 2 
 
Materials and Methods 
 
Mushroom Tyrosinase 
 
Mushroom tyrosinase (EC 1.14.18.1) was acquired from Sigma and used without further 
purification.  The enzyme was dissolved in 100% water and stored at 5 oC.  Initially, the 
concentration of protein in solution was determined by Bradford assay using bovine 
serum albumin as a standard [50].  A base-line rate was established as described later in 
the Material and Methods chapter under “Kinetic Assays of N-Acyltyramines Substrate 
Activity with Tyrosinase” where there was no EtOH added and 2 mM tyramine was used.  
Then to account for change in enzyme activity from day-to-day, and to account for the 
effect of 20% EtOH, a standard reaction was performed each day in the same manner as 
the baseline where tyramine was always 2 mM, this stock was dissolved in 100% water.  
The average of two correction activities was compared to the standards and a correction 
was multiplied into each reaction thereafter. 
  
Synthesis and Purification of N-Acyltyramines 
 
All substrates were synthesized using a modified approach published by Johnson et al 
(Scheme 4) [51, 52].  In general, tyramine was dissolved in acetonitrile and triethylamine, 
to which a 1:1 ratio of acylchloride was added drop wise, while vigorously stirred at 
room temperature.  After addition, the solution was allowed to stir for another 90 minutes 
before being evaporated under a stream of air.  Purification was accomplished by 
dissolving the product in methanol and running on a silica gel column in a gradient 
solvent system starting at 1% methanol in dichloromethane and progressing to 20% 
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methanol.  The final spot to elute, as checked on TLC run in dichlormethane:methanol 
(4:1) and visualized under UV light, was the desired product.  Yields for each are below: 
 
N-acetyltyramine – 40% 
N-propionyltyramine – 45% 
N-butyryltyramine – 80% 
N-pentanoyltyramine – 50% 
N-hexanoyltyramine – 50% 
 
N-Octanoyltyramine and N-decanoyltyramine were also synthesized, but due to 
extremely low water solubility (<< 1 nM in 20% EtOH), enzymatic activity assays were 
not possible, and these were not further characterized. 
 
Identity of synthesized substrates was confirmed and purity assessed by 1H and 13C NMR 
on iNOVA 400 MHz and processed on MestReNova (Appendix A). 
 
Scheme 4. Synthesis of N-acyltyramines.  R=CH3, C2H5, C3H7, C4H9, C5H11, C7H15, C9H19, Ph. 
 
Synthesis of N-benzoyltyramine 
 
Synthesis was identical to the N-acyltyramines.  It was not possible to find a solvent 
which would dissolve the crude product and allow for enzymatic assays; this was not 
characterized. 
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Kinetic Assay of L-3,4-Dihydroxyphenylalanine 
 
The reactions were conducted on a Yellow Springs Instrument Model 53 oxygen monitor 
which is outfitted to digitally output the O2 reading into Excel every second.  The oxygen 
electrode chamber was always prepared in the following order after cleaning and the 
positioning of the stir bar: water, phosphate buffer, ethanol and substrate.  The solution 
was capped with the oxygen electrode and allowed to stir while coming to equilibrium 
with the water bath at 37 oC.  Oxygen bubbles were aggregated and removed at least once 
and until there were no noticeable bubbles left.  Reaction conditions were 100 mM 
phosphate, pH=7.0, 0.025 mg/mL tyrosinase, and the indicated amount of substrate with 
a final reaction volume of 2 mL.  Background rates were determined with all components 
except enzyme present for 30 seconds followed by addition of tyrosinase over less than 
10 seconds.  Due to the small change in volume, data was not collected during this small 
window.  The reaction was then followed for two minutes.  All calculated slopes from 
Excel (Figure 4) were corrected for the amount of enzyme (0.05 mg for tyramine and 
0.025 mg for other substrates) and converted from %O2 to µmol/min/mg.  SigmaPlot was 
used to fit a Michaelis-Menten curve (Figure 5, Appendix B). 
 
Kinetic Assays of N-Acyltyramines Substrate Activity with Tyrosinase 
 
The general reaction conditions are identical to the L-DOPA assays with the following 
modifications: 20% ethanol, 100 mM phosphate, pH=7.0, 0.0125-0.025 mg/mL 
tyrosinase (all N-acyltyramines were dissolved in 100% EtOH and were conducted at 
0.0125 mg/mL tyrosinase, tyramine was dissolved in 100% water and was conducted at 
0.025 mg/mL tyrosinase) and the indicated amount of substrate with a final reaction 
volume of 2 mL (Appendix C).  Attempts were made to take substrate concentration from 
.1 to 10 times than KM, however, solubility constraints on N-pentanoyltyramine and N-
hexanoyltyramine made this impossible. 
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Product Determination 
 
A reaction mixture was allowed to react for 24 hours at room temperature containing 100 
mM phosphate, pH=7.0, 0.05 mg/mL tyrosinase, 20% ethanol and ~500mM N-
acetyltyramine.  The reaction was dried under a stream of air and the resulting brown 
solid vortexed exhaustively in 100% MeOD-d4.  1H and 13C NMR were done on iNOVA 
400 MHz and processed on MestReNova (Figure 8, 10).  The sample was dried under air 
and dissolved in 100% acetone-d6.  1H NMR was done on iNOVA 400 MHz and 
processed on MestReNova (Figure 11). 
 
Exploration of Enzymatic Lag 
 
Reactions were carried out as above in “Kinetic Assay of L-3,4-
dihydroxyphenylalanine.”  The substrate level was held at KM for each substrate and 
enzyme concentration was increased to the indicated amount (Appendix D). 
 
Modeling Experiments 
 
The crystal structure of mushroom tyrosinase (PDB ID 1WX2 [16]) was used for grid 
based ligand docking.  All co-crystallized ligands deemed superfluous for enzyme 
function were removed from the crystal structure and polar hydrogens were added using 
AutoDockTools.  Charges were then corrected for the requisite copper ions.  The receptor 
grid was prepared with a grid point spacing of 0.2 Å using AutoGrid.  The substrates of 
interest were then prepared using AutoDockTools to define torsions, rotamers and polar 
hydrogens.  The ligands were then docked into the active site of mushroom tyrosinase 
using AutoDock 4.0 [53, 54].  All default settings were utilized with the exception of 
increasing the number of energy evaluations from 2.5 x 104 to 2.5 x 107. 
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Chapter 3 
Results and Discussion 
 
Kinetic Evaluation of L-DOPA and N-Acyltyramines 
 
Results for the kinetic constants for the six compounds studied are shown in Table 1.  To 
verify the method, this process was done with the substrate L-DOPA, which is well 
studied in the literature. 
 
Figure 4: Processed oxygen electrode data for 50 mM tyramine with .05 mg tyrosinase.  Best-fit line 
formulas are shown which form the basis for determining reaction and background rates. 
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Figure 5. Michaelis-Menten plot of tyrosinase activity with tyramine. 
 
Table 1. Kinetic constants for N-acyltyramines.  L-DOPA (C9H11NO4), was used as a validation, table 
values are experimental but match literature values [19, 55]. 
Substrate KM (mM) Vmax 
(µmol/min/mg) 
Relative Vmax/KM 
L-DOPA  1.4 ± .38 140 ± 12 100 
Tyramine 6.6 ± .88 12 ± .48 1 
N-acetyltyramine 1.2 ± .27 37 ± 2.6 16.4 
N-propanoyltyramine 1.3 ± .13 19 ± .63 7.7 
N-butyryltyramine 2.3 ± .20 36 ± 1.2 8.2 
N-pentanoyltyramine 1.7 ± .28 19 ± 1.8 5.9 
N-hexanoyltyramine 1.9 ± .30 31 ± 2.7 8.6 
 
Results show that N-acyltyramines are stubstrates for tyrosinase.  It is clear that all the N-
acyltyramines had higher binding affinity and turnover values than tyramine.  There is 
little variation in Vmax/KM values; however, N-acetyltyramine exhibited the highest 
turnover and tightest binding values of the substituted tyramines.  The acyl chain length 
does not appear to have an effect on the binding properties, as all KMs are in the same 
range. 
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Docking Experiments 
 
Tyramine and N-acelytyramines with chain lengths between two and four carbons were 
docked into the mushroom tyrosinase crystal structure using AutoDock 4.0 (Figure 6) in 
order to evaluate their relative binding energies (Table 2).  The logarithmic nature of 
calculated binding energies indicates all KM values should be of the same magnitude, 
which is in agreement with experimental values. 
 
Table 2. Kinetic constants and calculated free energy of binding  for N-acyltyramines. 
Substrate KM (mM) Calculated Free Energy of 
Binding (kcal/mol) 
Tyramine 6.6 ± .9 -4.55 ± -2.5 
N-acetyltyramine 1.2 ± .3 -4.28 ± -2.5 
N-propanoyltyramine 1.3 ± .1 -4.43 ± -2.5 
N-butyryltyramine 2.3 ± .2 -4.29 ± -2.5 
N-pentanoyltyramine 1.7 ± .3 -4.37 ± -2.5 
N-hexanoyltyramine 1.9 ± .3 -4.72 ± -2.5 
 
 
Figure 6. Active site of tyrosinase with N-acetyltyramine bound.  Color scheme: Cu (orange), O2 
(red), hisitidines and bound N-acetyltyramine (generated from [16]). 
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Product Determination 
 
A reaction was conducted as described in “Product Determination” in the Materials and 
Methods section, where the solution was a dark brown color at the end.  The sample was 
dried under air leaving a brown solid which consisted of the product, unreacted N-
acetyltyramine, enzyme and buffer.  Only N-acetyltyramine and product would be 
expected to dissolve in MeOH; the solid was exhaustively vortexed in MeOD-d4 in 1H 
and 13C NMR taken on iNOVA 400 and processed with MestReNova (Figure 8, 10).  The 
NMR appears to be of a pure compound and the peaks can be assigned to the expected 
product as indicated for 1H (Figure 7, 8), and 13C (Figure 9, 10).  Note that in MeOD-d4, 
there is a pentet overlapping the expected triplet at 3.3 ppm, which makes integration 
unsuccessful.  Based on the 1H and 13C spectra, it was determined that the product was 1-
acetyl-2,3-dihydro-1H-indole-6,7-dione.  In order to verify that the product was a 
quinone rather than a diphenol, the sample was dried as before and dissolved in acetone-
d6; NMR was run on an iNOVA 400 and processed with MestReNova (Figure 11).  The 
resulting spectrum showed no evidence of an OH band suggesting that the compound is a 
quinone.  This is not an unreasonable outcome, as Borovanksy et al proposed cyclization 
after N-acetyldopamine is oxidized [28]. 
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Figure 7. Product structure: 1-acetyl-2,3-dihydro-1H-indole-6,7-dione with 1H predictions. 
 
 
Figure 8. 1H NMR spectrum in MeOD-d4 of tyrosinase reaction product where N-acetyltyramine was 
the substrate. 
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Figure 9. Product structure: 1-acetyl-2,3-dihydro-1H-indole-6,7-dione with 13C predictions. 
 
 
Figure 10. 13C NMR spectrum in MeOD-d4 of ryrosinase reaction product where N-acetyltyramine 
was the substrate in MeOD-d4. 
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Figure 11. 1H NMR spectrum in acetone-d6 of tyrosinase reaction product where N-acetyltyramine 
was the substrate in acetone-d6. 
 
Enzymatic Lag 
 
The reaction was conducted as described above in “Exploration of Enzymatic Lag” in 
Materials and Methods section as well as “Kinetic Assays.”  Each substrate was held at 
KM and tyrosinase concentration was increased.  This was not feasible with N-
pentanoyltyramine and N-hexanoyltyramine because their KM was roughly at the limit of 
solubility.  The oxygen electrode data is in Appendix D.  A graph of the lag times is 
shown in Figure 12.  Lag decreases as enzyme concentration increases, in agreement with 
the literature.  This is due to the low natural abundance of tyrosinase in the Eox state 
increasing.  Lag is shorter for acyltyramines over tyramine, but τ is unaffected by the 
change in chain length.  The decrease in lag is likely caused by the larger Vmax/KM 
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leading to faster accumulation of diphenol which can then generate Eox, the active form of 
the enzyme. 
 
 
Figure 12. Lag times for tyramine and N-acyltyramines with increasing tyrosinase. 
 
Conclusion 
 
N-acyltyramines were shown to be substrates for tyrosinase, suggesting that they could 
act as the precursors to N-acyldopamines.  Furthermore, N-acyltyramines have 
substantially higher Vmax/KM than tyramine; even though, changing the length of the 
substituent does not have a significant effect on KM or Vmax/KM values.  While τ is shorter 
for N-acyltyramines than for tyramine, changing chain lengths has no effect.  The 
observed decrease in lag can be attributed to higher Vmax/KM values for N-acyltyramines 
than tyramine.  The product is exactly what is expected after formation of N-
acyldopamine, which further supports N-acyltyramines as a precursor for N-
acyldopamines.  In order to get a more definitive answer, a study of N-acyltyrosines as 
precursors for N-acyldopamines should be conducted. 
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Appendix A: NMR Spectra 
 
Figure A-1. 1H NMR spectrum of N-acetyltyramine in MeOD-d4. 
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Figure A-2. 13C NMR spectrum of N-acetyltyramine in MeOD-d4. 
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 Figure A-3. 1H NMR spectrum of N-propanoyltyramine in MeOD-d4. 
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Figure A-4. 13C NMR spectrum of N-propanoyltyramine in MeOD-d4. 
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 Figure A-5. 1H NMR spectrum of N-butyryltyramine in MeOD-d4. 
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Figure A-6. 13C NMR spectrum of N-butyryltyramine in MeOD-d4. 
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 Figure A-7. 1H NMR spectrum of N-pentanoyltyramine in MeOD-d4. 
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 Figure A-8. 13C NMR spectrum of N-pentanoyltyramine in MeOD-d4. 
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 Figure A-9. 1H NMR spectrum of N-hexanoyltyramine in MeOD-d4. 
 
34 
 
 
Figure A-10. 13C NMR spectrum of N-hexanoyltyramine in MeOD-d4. 
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Appendix B: Michaelis-Menten Graphs 
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Figure B-1. Michaelis-Menten plot of tyrosinase activity with N-acetyltyramine. 
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Figure B-2. Michaelis-Menten plot of tyrosinase activity with N-propanoyltyramine. 
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Figure B-3. Michaelis-Menten plot of tyrosinase activity with N-butyryltyramine. 
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Figure B-4. Michaelis-Menten plot of tyrosinase activity with N-pentanoyltyramine. 
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Figure B-5. Michaelis-Menten plot of tyrosinase activity with N-hexanoyltyramine. 
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Appendix C: Oxygen Electrode Traces for Kinetic Parameters 
 
 
Figure C-1. Processed oxygen electrode data for 1 mM tyramine with .05 mg tyrosinase.  Best-fit line 
formulas are shown which form the basis for determining reaction and background rates. 
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Figure C-2. Processed oxygen electrode data for 2 mM tyramine with .05 mg tyrosinase.  Best-fit line 
formulas are shown which form the basis for determining reaction and background rates. 
 
Figure C-3. Processed oxygen electrode data for 5 mM tyramine with .05 mg tyrosinase.  Best-fit line 
formulas are shown which form the basis for determining reaction and background rates. 
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Figure C-4. Processed oxygen electrode data for 15 mM tyramine with .05 mg tyrosinase.  Best-fit 
line formulas are shown which form the basis for determining reaction and background rates. 
 
Figure C-5. Processed oxygen electrode data for 25 mM tyramine with .05 mg tyrosinase.  Best-fit 
line formulas are shown which form the basis for determining reaction and background rates. 
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Figure C-6. Processed oxygen electrode data for .15 mM N-acetyltyramine with .025 mg tyrosinase.  
Best-fit line formulas are shown which form the basis for determining reaction and background 
rates. 
 
Figure C-7. Processed oxygen electrode data for .31 mM N-acetyltyramine with .025 mg tyrosinase.  
Best-fit line formulas are shown which form the basis for determining reaction and background 
rates. 
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Figure C-8. Processed oxygen electrode data for .625 mM N-acetyltyramine with .025 mg tyrosinase.  
Best-fit line formulas are shown which form the basis for determining reaction and background 
rates. 
 
Figure C-9. Processed oxygen electrode data for 1.25 mM N-acetyltyramine with .025 mg tyrosinase.  
Best-fit line formulas are shown which form the basis for determining reaction and background 
rates. 
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Figure C-10. Processed oxygen electrode data for 2.5 mM N-acetyltyramine with .025 mg tyrosinase.  
Best-fit line formulas are shown which form the basis for determining reaction and background 
rates. 
 
Figure C-11. Processed oxygen electrode data for 5 mM N-acetyltyramine with .025 mg tyrosinase.  
Best-fit line formulas are shown which form the basis for determining reaction and background 
rates. 
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Figure C-12. Processed oxygen electrode data for 10 mM N-acetyltyramine with .025 mg tyrosinase.  
Best-fit line formulas are shown which form the basis for determining reaction and background 
rates. 
 
Figure C-13. Processed oxygen electrode data for .31 mM N-propanoyltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
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Figure C-14. Processed oxygen electrode data for .625 mM N-propanoyltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
 
Figure C-15. Processed oxygen electrode data for 1.25 mM N-propanoyltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
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Figure C-16. Processed oxygen electrode data for 2.5 mM N-propanoyltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
 
Figure C-17. Processed oxygen electrode data for 5 mM N-propanoyltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
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Figure C-18. Processed oxygen electrode data for 10 mM N-propanoyltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
 
Figure C-19. Processed oxygen electrode data for .31 mM N-butyryltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
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Figure C-20. Processed oxygen electrode data for .625 mM N-butyryltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
 
Figure C-21. Processed oxygen electrode data for 1.25 mM N-butyryltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
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Figure C-22. Processed oxygen electrode data for 2.5 mM N-butyryltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
 
Figure C-23. Processed oxygen electrode data for 5 mM N-butyryltyramine with .025 mg tyrosinase.  
Best-fit line formulas are shown which form the basis for determining reaction and background 
rates. 
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Figure C-24. Processed oxygen electrode data for 10 mM N-butyryltyramine with .025 mg tyrosinase.  
Best-fit line formulas are shown which form the basis for determining reaction and background 
rates. 
 
Figure C-25. Processed oxygen electrode data for .15 mM N-pentanoyltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
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Figure C-26. Processed oxygen electrode data for .31 mM N-pentanoyltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
 
Figure C-27. Processed oxygen electrode data for .625 mM N-pentanoyltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
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Figure C-28. Processed oxygen electrode data for 1.25 mM N-pentanoyltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
 
Figure C-29. Processed oxygen electrode data for 2 mM N-pentanoyltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
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Figure C-30. Processed oxygen electrode data for .15 mM N-hexanoyltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
 
Figure C-31. Processed oxygen electrode data for .31 mM N-hexanoyltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
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Figure C-32. Processed oxygen electrode data for .625 mM N-hexanoyltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
 
Figure C-33. Processed oxygen electrode data for 1.25 mM N-hexanoyltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
y = -0.0068x + 98.033 y = -0.1334x + 106.19
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Figure C-34. Processed oxygen electrode data for 1.75 mM N-hexanoyltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
 
Figure C-35. Processed oxygen electrode data for 2.5 mM N-hexanoyltyramine with .025 mg 
tyrosinase.  Best-fit line formulas are shown which form the basis for determining reaction and 
background rates. 
y = 4E-15x + 96.041 y = -0.2739x + 119.49
y = -0.0065x + 96.869 y = -0.2887x + 119.69
0
20
40
60
80
100
0 20 40 60 80 100 120 140 160 180 200
%
O
2
Time (s)
1.75 mM N-Hexanoyltyramine
.025 mg Tyrosinase
y = -0.0477x + 109.84 y = -0.3547x + 140.84
y = -0.0094x + 101.76 y = -0.2977x + 129.4
0
20
40
60
80
100
0 20 40 60 80 100 120 140 160 180 200
%
O
2
Time (s)
2.5 mM N-Hexanoyltyramine
.025 mg Tyrosinase
57 
 
 
 
 
Appendix D: Oxygen Electrode Traces for Lag Determination 
 
 
Figure D-1. Processed oxygen electrode data for 6.6 mM tyramine with .025 mg tyrosinase. 
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Figure D-2. Processed oxygen electrode data for 6.6 mM tyramine with .05 mg tyrosinase. 
 
 
Figure D-3. Processed oxygen electrode data for 6.6 mM tyramine with .075 mg tyrosinase. 
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Figure D-4. Processed oxygen electrode data for 6.6 mM tyramine with .1 mg tyrosinase. 
 
 
Figure D-5. Processed oxygen electrode data for 6.6 mM tyramine with .15 mg tyrosinase. 
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Figure D-6. Processed oxygen electrode data for 6.6 mM tyramine with .2 mg tyrosinase. 
 
 
Figure D-7. Processed oxygen electrode data for 1.2 mM N-acetyltyramine with .00625 mg tyrosinase. 
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Figure D-8. Processed oxygen electrode data for 1.2 mM N-acetyltyramine with .0125 mg tyrosinase. 
 
 
Figure D-9. Processed oxygen electrode data for 1.2 mM N-acetyltyramine with .025 mg tyrosinase. 
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Figure D-10. Processed oxygen electrode data for 1.2 mM N-acetyltyramine with .05 mg tyrosinase. 
 
 
Figure D-11. Processed oxygen electrode data for 1.2 mM N-acetyltyramine with .075 mg tyrosinase. 
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Figure D-12. Processed oxygen electrode data for 1.2 mM N-acetyltyramine with .1 mg tyrosinase. 
 
Figure D-13. Processed oxygen electrode data for 1.2 mM N-propanoyltyramine with .00625 mg 
tyrosinase. 
0
20
40
60
80
100
0 20 40 60 80 100 120 140 160 180 200
%
O
2
Time (s)
1.2 mM N-Acetyltyramine
.1 mg Tyrosinase 
0
20
40
60
80
100
0 20 40 60 80 100 120 140 160 180 200
%
O
2
Time (s)
1.3 mM N-Propanoyltyramine
.00625 mg Tyrosinase
64 
 
 
Figure D-14. Processed oxygen electrode data for 1.2 mM N-propanoyltyramine with .0125 mg 
tyrosinase. 
 
Figure D-15. Processed oxygen electrode data for 1.2 mM N-propanoyltyramine with .025 mg 
tyrosinase. 
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Figure D-16. Processed oxygen electrode data for 1.2 mM N-propanoyltyramine with .05 mg 
tyrosinase. 
 
Figure D-17. Processed oxygen electrode data for 1.2 mM N-propanoyltyramine with .075 mg 
tyrosinase. 
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Figure D-18. Processed oxygen electrode data for 1.2 mM N-propanoyltyramine with .15 mg 
tyrosinase. 
 
Figure D-19. Processed oxygen electrode data for 2.3 mM N-butyryltyramine with .0031 mg 
tyrosinase. 
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Figure D-20. Processed oxygen electrode data for 2.3 mM N-butyryltyramine with .0062 mg 
tyrosinase. 
 
Figure D-21. Processed oxygen electrode data for 2.3 mM N-butyryltyramine with .0125 mg 
tyrosinase. 
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Figure D-22. Processed oxygen electrode data for 2.3 mM N-butyryltyramine with .05 mg tyrosinase. 
 
Figure D-23. Processed oxygen electrode data for 2.3 mM N-butyryltyramine with .075 mg 
tyrosinase. 
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Figure D-24. Processed oxygen electrode data for 2.3 mM N-butyryltyramine with .1 mg tyrosinase. 
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